文献速递治疗药物监测与药物基因组学特殊人群用药药物不良反应与药物警戒

利培酮在自闭症谱系障碍儿童中治疗窗的外部验证

External validation of a therapeutic window for risperidone in children with autism spectrum disorder.
PubMed 文献 · Br J Clin Pharmacol · 2025-08-03

本研究利用德国TDM服务与TDM-VIGIL研究数据,对基于SPACe研究建立的利培酮及其活性代谢物9-OH-利培酮群体药动学模型及3.5-7 ng/mL治疗窗进行外部验证。结果显示模型个体预测较准确但群体预测低估利培酮浓度,ROC分析得出治疗窗为5.0-8.0 ng/mL,但作者建议维持原3.5-7.0 ng/mL。

要点

  • 利培酮群体药动学模型的个体预测较准确,适用于TDM。
  • ROC分析得出治疗窗5.0-8.0 ng/mL,但作者建议维持3.5-7.0 ng/mL。
  • 验证数据中低浓度合计谷浓度样本较少,需谨慎解读治疗窗。

核心结论

  • 该群体药动学模型似乎适合用于TDM,但群体预测低估利培酮浓度。
  • 基于ROC分析的治疗窗为5.0-8.0 ng/mL,但作者建议维持3.5-7.0 ng/mL。

研究设计与样本

  • 外部验证研究,使用德国TDM服务与TDM-VIGIL研究数据。
  • 采用非线性混合效应模型评估群体药动学模型性能,并用ROC分析定义治疗窗。

主要发现

  • 群体预测对利培酮浓度存在低估,但个体预测相当准确。
  • ROC分析得出的治疗窗为5.0-8.0 ng/mL。

关键数值与推荐

  • 原治疗窗为利培酮与9-OH-利培酮合计谷浓度3.5-7 ng/mL。
  • 外部验证ROC分析得出治疗窗5.0-8.0 ng/mL。

临床怎么用

  • 该群体药动学模型可用于利培酮TDM的个体预测。
  • 鉴于低浓度样本有限,建议继续沿用3.5-7.0 ng/mL治疗窗。

局限性

  • 分析中仅包含少量低合计谷浓度样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although risperidone is an effective pharmacological intervention for managing disruptive behaviour in children with autism spectrum disorder, it may induce metabolic side effects. This study aimed to externally validate the population pharmacokinetic (popPK) model and the therapeutic window of 3.5-7 ng/mL of risperidone and 9-OH-risperidone, developed with data of the SPACe Study. For this external validation, data from the German Therapeutic Drug Monitoring (TDM) Service and TDM-VIGIL Study was used in nonlinear mixed-effects modelling to evaluate popPK model performance and in receiver operating curve analyses to define the therapeutic window. Population predictions of the popPK model showed underprediction for risperidone concentrations, but individual predictions were fairly accurate. Receiver operating curve analyses resulted in a therapeutic window of 5.0-8.0 ng/mL. The popPK model seems suitable for use in TDM. Because the current analysis included only a few low sum trough concentrations, we suggest maintaining the therapeutic window of 3.5-7.0 ng/mL.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Hermans RA, Bruens K, Egberts KM, et al. External validation of a therapeutic window for risperidone in children with autism spectrum disorder. Br J Clin Pharmacol. 2025. PMID: 40879275. doi:10.1002/bcp.70130

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。